HEPA — Hepion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Hepion Pharmaceuticals Files Prospectus For Offering
Brief: Rencofilstat Produces Positive Outcomes In Translational Study On Idiopathic Pulmonary Fibrosis
Brief: Hepion Pharmaceuticals Announces Management Changes
Brief: Hepion Pharmaceuticals Says On July 21 Entered Into Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co As Sales Agent
U.S. STOCKS ON THE MOVE-Adobe, Nikola, copper miners
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
Hepion up as NASH drug study gets safety board's nod to proceed
Brief: Hepion Pharmaceuticals Announces Passing Of Key Safety Milestone In Phase 2B Trial Of Rencofilstat
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
Hepion Pharma surges after fatty liver disease drug meets trial goals
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill
Brief: Hepion Pharmaceuticals' NASH drug meets main goal in mid-stage trial
U.S. STOCKS ON THE MOVE-Hepion Pharma, AVROBIO, Volcon
Hepion's NASH drug meets main goal in mid-stage trial (updated)
Hepion Pharma up after fatty liver disease drug meets trial goals
Hepion NASH drug meets main goal in mid-stage trial
Hepion Pharma jumps as co to release mid-stage study results for NASH drug